Back to Search
Start Over
Cardiovascular and respiratory agents during pregnancy: implications for fetal development.
- Source :
-
Clinical and investigative medicine. Medecine clinique et experimentale [Clin Invest Med] 1985; Vol. 8 (4), pp. 339-44. - Publication Year :
- 1985
-
Abstract
- The management of common medical problems in pregnancy often requires adjustments in drug therapy to assure a healthy fetus. The management of steroid-dependent bronchial asthma in pregnancy requires oxygen supplementation as well as vigorous treatment of airway obstruction to protect the fetus from maternal hypoxemia. The hypertensive pregnant patient should discontinue dietary sodium restriction and diuretic therapy and should be managed with alphmethyldopa or beta-blocker therapy. Hydralazine may be added if hypertension is severe. Mitral valve prolapse appears to produce no difficulties during pregnancy and the use of prophylactic antibiotics is probably not necessary for routine vaginal delivery, unless complications occur. Digoxin and quinidine are safe to use in pregnancy, provided careful monitoring is maintained. Oral anticoagulants are contraindicated in pregnancy and should be replaced with heparin if pregnancy is desired.
- Subjects :
- Adrenergic beta-Antagonists therapeutic use
Adult
Anti-Bacterial Agents therapeutic use
Asthma drug therapy
Female
Fetus drug effects
Humans
Hypertension complications
Hypertension drug therapy
Methyldopa therapeutic use
Mitral Valve Prolapse complications
Mitral Valve Prolapse drug therapy
Pregnancy
Risk
Steroids therapeutic use
Asthma complications
Pregnancy Complications drug therapy
Pregnancy Complications, Cardiovascular drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 0147-958X
- Volume :
- 8
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Clinical and investigative medicine. Medecine clinique et experimentale
- Publication Type :
- Academic Journal
- Accession number :
- 2866859